Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) [Trend Analysis] luring active investment momentum, shares a decrease -0.51% to $1.94. Idera Pharmaceuticals, Inc. (IDRA) revealed that the presentation of new pre-clinical data that demonstrates the novel gene-silencing mechanism of action of the third generation antisense (3GA) technology platform.
In the presentation, entitled “Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides,” Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense.
This presentation also provided a demonstration of 3GA’s specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. Based on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. The total volume of 1.3 Million shares held in the session was surprisingly higher than its average volume of 469.60 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 10.80%, and looking further price to next year’s EPS is -4.50%. While take a short look on price to sales ratio, that was 289.91.
Shares of Aehr Test Systems (NASDAQ:AEHR) [Trend Analysis] runs in leading trade, it moving up 15.08% to traded at $1.97. The firm has price volatility of 11.78% for a week and 9.16% for a month. Its beta stands at 0.94 times. Aehr Test Systems (AEHR) revealed a development and manufacturing partnership between the two companies, including an investment by Semics in 200,000 shares of Aehr Test Systems common stock.
Aehr Test and Semics have a strategic partnership in place that includes a multi-year supply agreement for the development and manufacture of Aligners for Aehr Test’s multi-wafer FOX test and burn-in systems. The initial products resulting from this partnership have been delivered to customers and have been successfully implemented and qualified in a production environment, and the two companies expect to collaborate on additional wafer automation projects in the future. Narrow down four to firm performance, its weekly performance was 9.33% and monthly performance was 9.33%. The stock price of AEHR is moving up from its 20 days moving average with 8.66% and isolated positively from 50 days moving average with 14.08%.
Several matter pinch shares of Clovis Oncology, Inc. (NASDAQ:CLVS) [Trend Analysis], as shares plunging -2.91% to $22.36 with a share volume of 13.91 Million. Clovis Oncology Inc. were buoyed by the U.S. Food and Drug Administration accepting a fast-tracked new drug application for the company’s latest cancer drug.
The Boulder-based company’s (NASDAQ:CLVS) stock rose 27 percent after it announced the application acceptance for the drug rucaparib, used to treat advanced ovarian cancer in women with a certain genetic profile. Being accepted means an accelerated FDA review of the drug’s application and clinical trial data is scheduled to be finished by Feb. 23, 2017. Rucaparib is an oral drug for the treatment of ovarian cancer in women with tumors that have BRCA genetic mutations. The stock is going forward its 52-week low with 93.26% and moving down from its 52-week high price with -80.85%. To have technical analysis views, liquidity ratio of a company was calculated 5.50 as evaluated with its debt to equity ratio of 2.49. The float short ratio was 22.78%, as compared to sentiment indicator; Short Ratio was 6.57.